Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By Bristol-Myers Squibb Drug
This article was originally published in The Pink Sheet Daily
Executive SummaryIxempra already cleared for identical breast cancer indication.
You may also be interested in...
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?